EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma

Michael A Liu, Jennifer W Li, Karie Runcie

Current Oncology Reports · 2024

DOI: 10.1007/s11912-024-01523-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology Reports, 2024. Verfasst von Michael A Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Columbia University Irving Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA. Hauptthemen laut MEDLINE: Neoplasm Recurrence, Local, Urinary Bladder Neoplasms. Die Arbeit nennt 37 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health, Robert A. Winn Diversity in Clinical Trials Career Development Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: To summarize and evaluate the literature on treatment approaches for oligometastatic and locally recurrent urothelial cancer. RECENT FINDINGS: There is no clear definition for oligometastatic urothelial cancers due to limited data. Studies focusing on oligometastatic and locally recurrent urothelial cancer have been primarily retrospective. Treatment options include local therapy with surgery or radiation, and generalized systemic therapy such as chemotherapy or immunotherapy. Oligometastatic and locally recurrent urothelial cancers remain challenging to manage, and treatment requires an interdisciplinary approach. Systemic therapy is nearly always a component of current care in the form of chemotherapy, but the role of immunotherapy has not been explored. Consideration of surgical and radiation options may improve outcomes, and no studies have compared directly between the two localized treatment options. The development of new prognostic and predictive biomarkers may also enhance the treatment landscape in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm Recurrence, LocalUrinary Bladder NeoplasmsHumansCarcinoma, Transitional CellNeoplasm MetastasisImmunotherapyCombined Modality TherapyUrologic NeoplasmsPrognosis

Stichwörter der Autor:innen

Bladder cancerLocally recurrent diseaseOligometastatic diseaseUrothelial carcinoma

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Columbia University Irving Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA.
  • Department of Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.
  • Division of Hematology and Oncology, Columbia University Irving Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA. kr2836@cumc.columbia.edu.

Förderung

  • NIH HHS
  • National Institutes of Health
  • Robert A. Winn Diversity in Clinical Trials Career Development Award

Zitieren

APA

Liu, M. A., Li, J. W., & Runcie, K. (2024). Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma. Current Oncology Reports. https://doi.org/10.1007/s11912-024-01523-8

Vancouver

Liu MA, Li JW, Runcie K. Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma. Current Oncology Reports. 2024. doi:10.1007/s11912-024-01523-8

BibTeX
@article{Liu2024,
  author = {Liu, Michael A and Li, Jennifer W and Runcie, Karie},
  title = {Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma},
  journal = {Current Oncology Reports},
  year = {2024},
  doi = {10.1007/s11912-024-01523-8}
}
Kostenlos starten →